1800 202 8726
Understanding your molecular report

No Mutation Found — — What That Result Actually Means

Finding out that no mutation was detected on a molecular panel can feel like the test went wrong or that you have run out of options. Neither is true. A negative panel is a valid clinical result, and it shapes your treatment just as much as a positive one does.

Medically reviewed by Dr. Muralidhar Muddusetty, Surgical Oncologist, MBBS (AIIMS) · MS Surgery (AIIMS) · DNB Surg Onc · MRCS (Edinburgh) · Last reviewed September 2026

  • A result, not a failure — No mutation found is a complete clinical answer. Only a quality-control failure note on the report means the test itself did not work.
  • It rules things out — which matters — Knowing which targeted treatments do not apply to your tumour protects you from treatments unlikely to help and costs unlikely to benefit you.
  • Standard treatment is still available — Chemotherapy, immunotherapy where markers support it, radiation, and surgery are not blocked by a negative molecular result.
  • Retesting has a specific role — A repeat test is appropriate in defined circumstances — not routinely, and not simply because the result was negative.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Get this explained properly

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

A negative molecular panel is a valid clinical result, not a test failure. It tells your oncologist which targeted treatments are unlikely to help your cancer, so treatment can focus on the pathways the evidence supports for your type and stage. Standard treatment options remain open.

Does no mutation found mean the test did not work?

No. A negative result and a failed test are two different things. Your report would say something like 'insufficient material', 'QC failed', or 'test inconclusive' if the laboratory could not produce a reliable result. A clear statement that no actionable mutation was detected means the test completed successfully and found what it was looking for — nothing.

Most people who undergo comprehensive molecular panel testing do not carry an actionable mutation. ASCO and NCCN guidance treats a negative panel as the expected result for the majority of cancer types tested. This is not news that your cancer is untreatable. It is information that confirms which treatment pathway your oncologist will follow.

What treatments are available when no targetable mutation is found?

A negative molecular panel does not close off treatment. For most cancer types, the first-line approach — surgery, chemotherapy, radiation, or a combination — does not depend on finding a specific mutation. Your oncologist will recommend the pathway with the strongest evidence for your cancer type and stage.

Immunotherapy may still be an option. Even when no targeted mutation is found, markers such as PD-L1 expression, microsatellite instability, and tumour mutational burden are often checked on the same panel. A result on any of those can make immunotherapy appropriate for you. If your oncologist has not yet explained what those markers showed, ask at your next appointment.

What do the terms on your negative report actually mean?

Wild-type
The gene was tested and found in its normal, unmutated form. When a gene is reported as wild-type, no mutation was present in that specific gene.
Variant of unknown significance (VUS)
A change was found in a gene, but the evidence is not yet strong enough to say whether it causes cancer or affects treatment. It is neither clearly harmful nor clearly harmless, and its classification can change as research develops.
Actionable mutation
A genetic change for which a specific targeted treatment is known to work. A negative panel means none of these were found in the genes that were tested.
Tumour mutational burden (TMB)
A count of the total number of mutations the tumour carries overall — not a single targeted mutation. A high TMB can indicate that immunotherapy may help, even when no specific targetable gene mutation is found.
Microsatellite instability (MSI)
A marker of how the tumour repairs its DNA. A high MSI result can open immunotherapy as an option even when no targetable mutation was found. It is usually reported on the same panel.
Panel
The specific list of genes the laboratory examined. A negative result is meaningful only for the genes on that panel. Genes not included were not checked.

Still unclear?

Send your reports across and a specialist will walk you through what they mean — what is known, what is not, and what the options actually are.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

What do the different phrases on a negative report mean?

Report phraseWhat it meansWhat happens next
Wild-type / No pathogenic variant detectedThe gene tested was in its normal form; no mutation presentTreatment follows evidence-based protocols for your cancer type and stage
Variant of unknown significance (VUS)A change was found but its clinical impact is not yet establishedYour team notes it; family history may be reviewed; no immediate treatment change is typically required
Insufficient material / QC failedThe DNA sample was too small or degraded — the only scenario where the test itself did not workA repeat biopsy may be needed before molecular data can inform treatment planning
Gene not on panelThis gene was not included in the test you hadIf a specific mutation is suspected, a targeted single-gene test can be ordered separately

What questions should you ask after a negative molecular result?

  • Ask which genes were tested and which were not included on this panel.
  • Ask whether immunotherapy markers — PD-L1 expression, MSI, and TMB — were checked and what they showed.
  • Ask whether any variant of unknown significance was found and how your team is monitoring it.
  • Ask what the recommended treatment pathway is for your cancer type and stage without a targetable mutation.
  • Ask whether a molecular tumour board review would be appropriate for your case.
  • Tell your team about every supplement, herbal preparation, and over-the-counter medicine you are taking.

Did you know?

For the majority of patients who undergo comprehensive molecular panel testing, no actionable mutation is identified.

ASCO and NCCN both note that this is the expected result across most cancer types — and that it informs treatment just as clearly as a positive finding, by ruling out therapies unlikely to help.

Source: ASCO and NCCN Guidelines on Molecular Testing and Targeted Therapy

Explore 112 more Markers, Molecular Testing and Test Accuracy topics

HUB — How Accurate Is a Biopsy? Repeats, Errors and Second Opinions

HUB — IHC and Molecular Markers on a Biopsy

HUB — Labs, Slides and Second Opinions on a Biopsy

All Markers, Molecular Testing and Test Accuracy →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

Does no mutation found mean there is nothing that can be done?

No. A negative molecular panel does not mean your cancer is untreatable. For most cancers, the first-line approach — surgery, chemotherapy, radiation, or a combination — does not depend on finding a specific mutation. A negative result tells your oncologist that a particular class of targeted drugs is unlikely to help. It does not cancel the other treatment pathways, which remain available based on your cancer type, stage, and general health.

Should we pay for a broader or international molecular test?

That depends on which genes were on your original panel and whether your oncologist believes a gene not covered could be clinically relevant for your cancer type. A broader panel tests more genes, but more genes does not automatically mean more useful information — the question is whether those additional genes matter for your specific diagnosis. Before ordering a repeat test, ask which genes were not covered and whether testing them would change treatment decisions. The cost is significant, and a second test is not always clinically justified.

What is a variant of unknown significance and should we be worried?

A variant of unknown significance, or VUS, is a genetic change found in the tumour whose clinical meaning is not yet established. It is not the same as a harmful mutation, and it does not mean your cancer is more aggressive or that a specific treatment is needed. Your team will note it and may ask about your family's cancer history, as some VUS findings are relevant to hereditary risk assessments. The scientific understanding of VUS findings changes as more data is published, and classification can shift over time.

The report says wild-type. Is that good news?

Wild-type means the gene tested was found in its normal, unmutated form. Whether that is reassuring depends on the gene and your cancer type. For some genes, a wild-type result rules out a treatment option. For others, it simply confirms the gene is not driving your cancer and is not relevant to your case. Your oncologist can explain what a wild-type result on a specific gene means for your situation, because the answer depends on which gene it is and which cancer you have.

We spent a large amount on this test and the result was negative. Was it money wasted?

A negative molecular result is not wasted money. The test answered a clinical question — are there targetable mutations in your tumour — and no is a valid, clinically useful answer. It means treatment can proceed on the right pathway rather than trying targeted agents that would cause side effects without benefit. Molecular testing costs are indicative and change over time. If cost is a concern, ask your oncologist whether the full panel was necessary for your cancer type, or whether a more focused test would have answered the same question.

Should we retest if the cancer progresses or comes back?

This is worth raising with your oncologist. Tumours can acquire new mutations as they grow or after treatment, so a new biopsy taken at progression may find mutations not present at diagnosis. New targeted agents are also approved regularly, which means genes with no available treatment when you were first tested may have options now. Retesting routinely after a negative result is not the standard approach, but retesting when the disease changes is a recognised part of molecular oncology practice.

Full index

Browse all 701 biopsy topics

Every page in this section, grouped by the part of the journey it belongs to. Pick a group to see what is in it.

What Is a Biopsy?

What Is a Biopsy? Everything You Need to Know →

Types of Biopsy Compared

Which Biopsy Will You Have? Techniques Compared →

Preparing for a Biopsy

What to Expect on the Day of Your Biopsy →

Recovery and Aftercare

After a Biopsy: Recovery, Aftercare and Warning Signs →

Biopsy by Body Part

Biopsy by Body Part: What to Expect at Each Site →

Understanding Your Report

How to Read a Biopsy Report: Terms Explained →

IHC and Molecular Markers

IHC and Molecular Markers on a Biopsy: What They Mean →

Grading and Scoring Systems

Cytology & Prostate Scoring Systems Explained →

How Accurate Is a Biopsy?

How Accurate Is a Biopsy? Errors and Second Opinions →

If Your Result Is Benign

Your Biopsy Is Benign: What It Means and What Comes Next →

Call now Book free consultation